What are the side effects of Remibrutinib-RHAPSIDO?

Remibrutinib-RHAPSIDO is a new BTK inhibitor. Some common adverse reactions have been observed in clinical studies, including nasopharyngitis, bleeding, headache, nausea and abdominal pain. The incidence of these side effects has been documented in clinical trials and patients need to be careful when using this drug.

First, the risk of bleeding is an important consideration when treating remibrutinib. During treatment, doctors and patients should pay great attention to the risk of bleeding. If bleeding is observed during treatment, remibrutinib should be discontinued immediately and a decision should be made as to whether to resume treatment after assessing the risk of bleeding versus the potential benefit of treatment. In addition, patients should suspend remibrutinib treatment for 3 to 7 days before and after surgery or other invasive procedures to reduce the risk of bleeding.

Second, the risk of bleeding may be increased when remibrutinib is used concomitantly with antithrombotic drugs. Therefore, in this situation, the benefits of antithrombotic drugs should be carefully weighed against the risks of coadministration with remibrutinib, and patients should be regularly monitored for signs and symptoms of bleeding.

Finally, there are insufficient data regarding the use of live or live-attenuated vaccines in patients receiving remibrutinib. For safety reasons, patients receiving treatments such as Sjögren's syndrome should avoid the use of live and live-attenuated vaccines to prevent unnecessary complications.

In summary, although remibrutinib has shown good efficacy in clinical application, patients need to be cautious about its possible side effects during use, especially the risk of bleeding and vaccination issues. During treatment, patients should maintain good communication with their doctors, jointly monitor possible adverse reactions, and adjust treatment plans according to medical advice to ensure the safety and effectiveness of treatment.

Reference materials:https://www.drugs.com/rhapsido.html